Clinical Commander

Back to dossier
heme.aplastic-anemia.core.v1PRODUCTION
heme.aplastic-anemia.core.v1

Aplastic Anaemia / Acquired Bone-Marrow Failure (SAA / vSAA — chronic + subacute)

hematologychronicsubacuteadultpediatric
Hard-required inputs
0 / 7
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Frame as acquired bone-marrow failure: pancytopenia + hypocellular marrow without fibrosis/infiltration/dysplasia. Establish acquired vs inherited, severity tier pending, primary vs secondary (drug/toxin/viral/pregnancy/seronegative-hepatitis) (BSH 2024 PMID 38247114; DeZern PMID 34156438)

Inputs
2
Actions
1
Advance rule
Set
Advance when

Bone-marrow-failure framing assigned

Patient inputs (13)

Hypocellular (<25%) marrow without fibrosis/infiltration/dysplasia is the diagnostic core; cytogenetics + dysplasia exclude hypoplastic MDS (BSH 2024 PMID 38247114; DeZern PMID 34156438)

Treatment fork: young (matched-sibling HSCT first-line) vs older (IST-favoured); paediatric mandates inherited-marrow-failure screen (ASTCT 2024 PMID 39307421; BSH paeds amendment PMID 29285764)

Pancytopenia confirmation; ANC drives Camitta severity (SAA ANC<500, vSAA ANC<200) (Camitta PMID 2893118)

Camitta severity (absolute retic <20×10⁹/L or <1%) — distinguishes hypoproliferative failure from haemolysis (Camitta PMID 2893118)

Febrile neutropenia in SAA = medical emergency → empiric broad-spectrum antipseudomonal within 60 min (BSH 2024 PMID 38247114)

Camitta severity tier + neutropenic-sepsis risk (Camitta PMID 2893118; BSH 2024 PMID 38247114)

Camitta severity (plt<20k) + intracranial-bleed risk (plt<10k transfusion threshold) (BSH 2024 PMID 38247114)

GPI-anchor flow cytometry: PNH clone present in ~1/3 of AA at diagnosis — overlap; quantify + monitor (DeZern PMID 34156438)

Family history, short stature, nail/skin/oral changes, café-au-lait, early grey hair → Fanconi chromosomal-breakage (DEB/MMC), telomere length (dyskeratosis congenita), GATA2/SDS — alters conditioning dose (BSH paeds PMID 29285764; DeZern PMID 34156438)

Offending drug/toxin (chloramphenicol, benzene, NSAIDs, antithyroid), seronegative hepatitis (3-12 wk antecedent icteric illness), pregnancy → secondary-AA aetiology (BSH 2024 PMID 38247114; hep-AA PMID 32925550)

Pregnancy-associated AA: supportive ± ciclosporin; defer ATG; affects IST timing (BSH 2024 PMID 38247114)

Seronegative hepatitis-associated AA: antecedent transaminitis — fulminant variant possible (hep-AA series PMID 32925550)

HLA-matched sibling availability is the pivot for first-line allogeneic HSCT in young SAA/vSAA (ASTCT 2024 PMID 39307421)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningvery_severe_aa_anc_lt_200
    Very-severe AA: hypocellular marrow + ANC <0.2×10⁹/L (plus SAA criteria) (Camitta PMID 2893118)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningfebrile_neutropenia_in_saa
    Temperature ≥38.0°C with ANC <0.5×10⁹/L in SAA/vSAA (BSH 2024 PMID 38247114)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningfulminant_hepatitis_associated_aa
    Rapidly progressive marrow failure with antecedent/concurrent seronegative hepatitis ± hepatic failure (hep-AA series PMID 32925550)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereintracranial_bleed_risk_plt_lt_10k
    Platelets <10×10⁹/L (or <20×10⁹/L with bleeding/fever) (BSH 2024 PMID 38247114)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereclonal_evolution_to_mds_aml
    New circulating blasts / emerging dysplasia / acquired cytogenetic clone on surveillance (DeZern PMID 34156438)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereexpanding_pnh_clone_with_hemolysis
    Expanding GPI-deficient PNH clone with intravascular haemolysis / thrombosis in an AA patient (DeZern PMID 34156438)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

MONITORINGoptionalDrives monitoring threshold
Loading…

Recommended regimen

Aplastic Anaemia Definitive Therapy (IST triplet + TPO-RA + supportive)
axis: aa_definitive_therapy
Selected axis "Aplastic Anaemia Definitive Therapy (IST triplet + TPO-RA + supportive)" by default fallback (first axis)
  • horse antithymocyte globulin (lymphocyte immune globulin, ATGAM)
    first line
    polyclonal_antithymocyte_globulin
    40 mg/kg/day IV × 4 consecutive days • IV • daily × 4 days
    triggers: SAA_or_vSAA, no_HLA_matched_sibling_or_HSCT_ineligible
    Horse-ATG backbone of first-line IST — superior to rabbit-ATG (Scheinberg NEJM 2011 PMID 21812672: 6-mo ORR 68% vs 37%, 3-y survival 96% vs 76%). Premedicate (steroid/antihistamine); monitor serum sickness d7-14 (BSH 2024 PMID 38247114).
    rxcui 1011
  • ciclosporin (cyclosporine)
    first line
    calcineurin_inhibitor
    5 mg/kg/day PO divided BID (trough-adjusted ~200-400 ng/mL) • PO • BID
    triggers: SAA_or_vSAA, IST_pathway, non_severe_AA_requiring_treatment
    Calcineurin inhibitor — second pillar of IST with horse-ATG; continue ≥12 mo then taper SLOWLY to limit relapse (BSH 2024 PMID 38247114; RACE PMID 34986284). Monitor trough, renal function, BP.
    rxcui 3008
  • eltrombopag
    first line
    thrombopoietin_receptor_agonist
    150 mg PO once daily (75 mg East-Asian ancestry); from day 1 • PO • once daily
    triggers: SAA_or_vSAA, IST_pathway, refractory_to_IST_alone
    TPO-RA added UPFRONT to hATG + CsA — RACE NEJM 2022 PMID 34986284: 3-mo CR 22% vs 10%, 6-mo ORR 68% vs 41%, faster response (median 3.0 vs 8.8 mo); Townsley NEJM 2017 PMID 28423296 day-1 cohort 6-mo CR 58%/ORR 94%. Monitor LFTs + clonal evolution (BSH 2024 PMID 38247114).
    rxcui 711942
  • rabbit antithymocyte globulin (Thymoglobulin)
    second line
    polyclonal_antithymocyte_globulin
    3.5 mg/kg/day IV × 5 days (HSCT conditioning) or salvage IST • IV • daily × 5 days
    triggers: relapsed_or_refractory_after_horse_ATG, HSCT_conditioning_serotherapy
    Inferior to horse-ATG as first-line IST (Scheinberg PMID 21812672) — reserved for salvage IST or as serotherapy within HSCT conditioning where rabbit-ATG is preferred (ASTCT 2024 PMID 39307421).
    rxcui 225741
  • romiplostim
    second line
    thrombopoietin_receptor_agonist
    10 mcg/kg SC weekly, titrate • SC • weekly
    triggers: refractory_AA, eltrombopag_intolerant_or_unavailable
    Alternative TPO-RA in refractory AA where eltrombopag is not tolerated/available; monitor for clonal evolution (BSH 2024 PMID 38247114).
    rxcui 805452
  • prednisolone
    add on
    corticosteroid
    1 mg/kg/day PO (ATG cover; serum-sickness short course) • PO • daily, tapered
    triggers: ATG_premedication, ATG_serum_sickness_d7_14
    Short corticosteroid course with ATG to attenuate cytokine-release and serum sickness (NOT disease-modifying monotherapy) (BSH 2024 PMID 38247114).
    rxcui 8638
  • filgrastim (G-CSF)
    rescue
    granulocyte_colony_stimulating_factor
    5 mcg/kg/day SC (short course) • SC • daily
    triggers: severe_neutropenic_sepsis_unresponsive, bridging_only
    Adjunct in severe infection/sepsis only — does NOT improve survival or response and routine use discouraged (clonal-evolution concern); no substitute for definitive therapy (BSH 2024 PMID 38247114).
    rxcui 68442
  • danazol
    second line
    attenuated_androgen
    200 mg PO BID-TID • PO • BID-TID
    triggers: IST_and_HSCT_ineligible, telomere_biology_disorder, palliative_supportive
    Androgen — historical / supportive role; rational in telomere-biology disorders (dyskeratosis congenita) and where IST/HSCT not feasible; monitor LFTs, virilisation (BSH 2024 PMID 38247114; DeZern PMID 34156438).
    rxcui 3102
  • oxymetholone
    second line
    anabolic_androgen
    1-5 mg/kg/day PO • PO • daily
    triggers: IST_and_HSCT_ineligible, resource_limited_setting, palliative_supportive
    Anabolic androgen — supportive option where IST/HSCT unavailable; hepatotoxicity / virilisation monitoring (BSH 2024 PMID 38247114).
    rxcui 7813
  • allogeneic haematopoietic stem-cell transplantation (HLA-matched sibling / matched-unrelated / haploidentical)
    first line
    cellular_therapy
    triggers: SAA_or_vSAA_young_with_HLA_matched_sibling, refractory_to_IST, inherited_marrow_failure_with_dose_reduced_conditioning
    Curative for vSAA/SAA — first-line in young patients with HLA-matched sibling (5-y OS >90%); bone-marrow graft + rabbit-ATG conditioning preferred; Fanconi/IBMFS REQUIRES alkylator/irradiation DOSE-REDUCTION to avoid fatal toxicity (ASTCT 2024 PMID 39307421; BSH paeds PMID 29285764).
  • irradiated leucodepleted CMV-safe blood products (pRBC / platelets)
    first line
    transfusion_support
    triggers: symptomatic_anemia, platelets_below_10k_or_bleeding, HSCT_candidate_use_CMV_safe_irradiated
    Restrictive thresholds; irradiated + leucodepleted + CMV-safe if potential HSCT candidate; AVOID family-donor products pre-HSCT (alloimmunisation/graft-rejection risk) (BSH 2024 PMID 38247114; ASTCT 2024 PMID 39307421).
  • iron-chelation therapy (transfusional iron overload)
    add on
    iron_chelation
    triggers: transfusion_dependent, ferritin_persistently_elevated
    Manage transfusional iron overload in transfusion-dependent AA; weigh cytopenia/marrow effects of chelator choice (BSH 2024 PMID 38247114).

outpatient playbook — drug actions (4)

  1. 1. ciclosporin
    rxcui 3008
    5 mg/kg/day PO divided BID (trough-adjusted) • PO • BID
    trigger: IST pathway / non-severe AA requiring treatment
    Calcineurin-inhibitor pillar of IST (BSH 2024 PMID 38247114)
  2. 2. eltrombopag
    rxcui 711942
    150 mg PO daily (75 mg East-Asian) • PO • once daily
    trigger: IST pathway — upfront with hATG + CsA
    RACE NEJM 2022 PMID 34986284 — added upfront improves ORR/CR
  3. 3. danazol
    rxcui 3102
    200 mg PO BID-TID • PO • BID-TID
    trigger: IST/HSCT-ineligible or telomere-biology disorder
    Androgen supportive option (DeZern PMID 34156438)
  4. 4. iron chelation
    Per chelator protocol • PO • daily
    trigger: Transfusion-dependent + ferritin persistently elevated
    Transfusional iron-overload management (BSH 2024 PMID 38247114)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Pancytopenia (≥2 lineages cytopenic) on CBC — bone-marrow failure differential (BSH 2024 PMID 38247114); Isolated or bilineage cytopenia progressing to pancytopenia (DeZern Blood Adv 2021 PMID 34156438); Petechiae / mucosal bleeding from severe thrombocytopenia (BSH 2024 PMID 38247114).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Aplastic Anaemia / Acquired Bone-Marrow Failure (SAA / vSAA — chronic + subacute)** (heme.aplastic-anemia.core.v1).
Phenotype framing: Partition pancytopenia + hypocellular marrow: acquired AA (idiopathic), hypoplastic MDS (cytogenetic clone / dysplasia / somatic mutations), PNH / AA-PNH overlap (GPI-deficient clone, haemolysis), inherited marrow failure (Fanconi / dyskeratosis congenita / SDS / GATA2), drug/toxin/radiation-induced, seronegative hepatitis-associated, large-granular-lymphocyte leukaemia, hypocellular-presenting acute leukaemia, B12/copper deficiency, infiltrative/fibrotic marrow, pregnancy-associated, autoimmune (SLE) (BSH 2024 PMID 38247114; DeZern PMID 34156438)
Scope: Frame as acquired bone-marrow failure: pancytopenia + hypocellular marrow without fibrosis/infiltration/dysplasia. Establish acquired vs inherited, severity tier pending, primary vs secondary (drug/toxin/viral/pregnancy/seronegative-hepatitis) (BSH 2024 PMID 38247114; DeZern PMID 34156438)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Aplastic Anaemia Definitive Therapy (IST triplet + TPO-RA + supportive)**.
1. horse antithymocyte globulin (lymphocyte immune globulin, ATGAM) 40 mg/kg/day IV × 4 consecutive days IV daily × 4 days (polyclonal_antithymocyte_globulin, first line) — Horse-ATG backbone of first-line IST — superior to rabbit-ATG (Scheinberg NEJM 2011 PMID 21812672: 6-mo ORR 68% vs 37%, 3-y survival 96% vs 76%). Premedicate (steroid/antihistamine); monitor serum sickness d7-14 (BSH 2024 PMID 38247114).
2. ciclosporin (cyclosporine) 5 mg/kg/day PO divided BID (trough-adjusted ~200-400 ng/mL) PO BID (calcineurin_inhibitor, first line) — Calcineurin inhibitor — second pillar of IST with horse-ATG; continue ≥12 mo then taper SLOWLY to limit relapse (BSH 2024 PMID 38247114; RACE PMID 34986284). Monitor trough, renal function, BP.
3. eltrombopag 150 mg PO once daily (75 mg East-Asian ancestry); from day 1 PO once daily (thrombopoietin_receptor_agonist, first line) — TPO-RA added UPFRONT to hATG + CsA — RACE NEJM 2022 PMID 34986284: 3-mo CR 22% vs 10%, 6-mo ORR 68% vs 41%, faster response (median 3.0 vs 8.8 mo); Townsley NEJM 2017 PMID 28423296 day-1 cohort 6-mo CR 58%/ORR 94%. Monitor LFTs + clonal evolution (BSH 2024 PMID 38247114).
4. rabbit antithymocyte globulin (Thymoglobulin) 3.5 mg/kg/day IV × 5 days (HSCT conditioning) or salvage IST IV daily × 5 days (polyclonal_antithymocyte_globulin, second line) — Inferior to horse-ATG as first-line IST (Scheinberg PMID 21812672) — reserved for salvage IST or as serotherapy within HSCT conditioning where rabbit-ATG is preferred (ASTCT 2024 PMID 39307421).
5. romiplostim 10 mcg/kg SC weekly, titrate SC weekly (thrombopoietin_receptor_agonist, second line) — Alternative TPO-RA in refractory AA where eltrombopag is not tolerated/available; monitor for clonal evolution (BSH 2024 PMID 38247114).
6. prednisolone 1 mg/kg/day PO (ATG cover; serum-sickness short course) PO daily, tapered (corticosteroid, add on) — Short corticosteroid course with ATG to attenuate cytokine-release and serum sickness (NOT disease-modifying monotherapy) (BSH 2024 PMID 38247114).
7. filgrastim (G-CSF) 5 mcg/kg/day SC (short course) SC daily (granulocyte_colony_stimulating_factor, rescue) — Adjunct in severe infection/sepsis only — does NOT improve survival or response and routine use discouraged (clonal-evolution concern); no substitute for definitive therapy (BSH 2024 PMID 38247114).
8. danazol 200 mg PO BID-TID PO BID-TID (attenuated_androgen, second line) — Androgen — historical / supportive role; rational in telomere-biology disorders (dyskeratosis congenita) and where IST/HSCT not feasible; monitor LFTs, virilisation (BSH 2024 PMID 38247114; DeZern PMID 34156438).
9. oxymetholone 1-5 mg/kg/day PO PO daily (anabolic_androgen, second line) — Anabolic androgen — supportive option where IST/HSCT unavailable; hepatotoxicity / virilisation monitoring (BSH 2024 PMID 38247114).
10. allogeneic haematopoietic stem-cell transplantation (HLA-matched sibling / matched-unrelated / haploidentical) (cellular_therapy, first line) — Curative for vSAA/SAA — first-line in young patients with HLA-matched sibling (5-y OS >90%); bone-marrow graft + rabbit-ATG conditioning preferred; Fanconi/IBMFS REQUIRES alkylator/irradiation DOSE-REDUCTION to avoid fatal toxicity (ASTCT 2024 PMID 39307421; BSH paeds PMID 29285764).
11. irradiated leucodepleted CMV-safe blood products (pRBC / platelets) (transfusion_support, first line) — Restrictive thresholds; irradiated + leucodepleted + CMV-safe if potential HSCT candidate; AVOID family-donor products pre-HSCT (alloimmunisation/graft-rejection risk) (BSH 2024 PMID 38247114; ASTCT 2024 PMID 39307421).
12. iron-chelation therapy (transfusional iron overload) (iron_chelation, add on) — Manage transfusional iron overload in transfusion-dependent AA; weigh cytopenia/marrow effects of chelator choice (BSH 2024 PMID 38247114).

Setting playbook (outpatient) — Confirm acquired AA + exclude hypoplastic MDS / PNH / IBMFS; stratify Camitta severity; deliver IST monitoring + supportive care + clonal-evolution surveillance for non-severe / stable AA (BSH 2024 PMID 38247114)
13. ciclosporin 5 mg/kg/day PO divided BID (trough-adjusted) PO BID — IST pathway / non-severe AA requiring treatment (Calcineurin-inhibitor pillar of IST (BSH 2024 PMID 38247114))
14. eltrombopag 150 mg PO daily (75 mg East-Asian) PO once daily — IST pathway — upfront with hATG + CsA (RACE NEJM 2022 PMID 34986284 — added upfront improves ORR/CR)
15. danazol 200 mg PO BID-TID PO BID-TID — IST/HSCT-ineligible or telomere-biology disorder (Androgen supportive option (DeZern PMID 34156438))
16. iron chelation Per chelator protocol PO daily — Transfusion-dependent + ferritin persistently elevated (Transfusional iron-overload management (BSH 2024 PMID 38247114))

Non-pharmacologic actions:
- Irradiated leucodepleted CMV-safe transfusion at restrictive thresholds; avoid family-donor products if HSCT candidate (BSH 2024 PMID 38247114; ASTCT 2024 PMID 39307421)
- Antifungal + antiviral + anti-pneumocystis prophylaxis per neutropenia depth/duration (BSH 2024 PMID 38247114)
- Vaccination + fertility counselling (BSH 2024 PMID 38247114)
- Paediatric → adult care transition planning (BSH paeds PMID 29285764)

AVOID / contraindication checks:
- Avoid family donor blood products pre HSCT — alloimmunisation/graft rejection risk (ASTCT 2024 PMID 39307421)
- Fanconi anaemia / inherited marrow failure — DOSE REDUCE alkylator + irradiation conditioning (life threatening toxicity at standard dose) (BSH paeds PMID 29285764)
- Eltrombopag — serial cytogenetics/marrow clonal evolution monitoring (MDS/AML) + LFTs (BSH 2024 PMID 38247114)
- Horse ATG — premedicate (steroid/antihistamine); monitor anaphylaxis + serum sickness d7 14 (BSH 2024 PMID 38247114)
- Ciclosporin — trough levels + renal function + BP + drug interactions (BSH 2024 PMID 38247114)
- Pregnancy — defer ATG; supportive ± ciclosporin; specialist co management (BSH 2024 PMID 38247114)
- G CSF — not disease modifying; routine/prolonged use discouraged (clonal evolution concern) (BSH 2024 PMID 38247114)

Monitoring

Regimen monitoring:
- CBC + differential + reticulocyte weekly during IST induction then per response (first response often 3-6 mo) (RACE PMID 34986284)
- Ciclosporin trough + renal/hepatic function + BP q1-2w during titration then monthly (BSH 2024 PMID 38247114)
- Eltrombopag LFTs q2w initially; clonal-evolution surveillance — marrow + cytogenetics if cytopenias worsen / dysplasia emerges (BSH 2024 PMID 38247114)
- Serial peripheral-blood PNH-clone flow cytometry (DeZern PMID 34156438)
- Ferritin + transfusion burden in transfusion-dependent patients (BSH 2024 PMID 38247114)
- ATG serum-sickness watch d7-14 post-infusion (BSH 2024 PMID 38247114)
- Long-term periodic marrow + cytogenetics for clonal evolution (MDS/AML) and relapse (BSH 2024 PMID 38247114)

Setting (outpatient) monitoring:
- CBC + reticulocyte per response (first response 3-6 mo on IST) (RACE PMID 34986284)
- Ciclosporin trough + renal function monthly when stable (BSH 2024 PMID 38247114)
- Eltrombopag LFTs + clonal-evolution surveillance (BSH 2024 PMID 38247114)
- Serial PNH-clone flow + periodic marrow cytogenetics for MDS/AML evolution (DeZern PMID 34156438)

Follow-up plan: Long-term clonal-evolution surveillance (MDS/AML/PNH — periodic marrow + cytogenetics + flow); response reassessment at 3/6/12 mo (re-treat or escalate non-responders); taper ciclosporin slowly to limit relapse; vaccination/fertility counselling; transition paediatric → adult care; lifelong haematology follow-up given late clonal/relapse risk (BSH 2024 PMID 38247114; ASTCT 2024 PMID 39307421)
- Close-out criterion: Long-term surveillance plan documented

Monitoring phase: CBC + differential + reticulocyte (response timing — first response often 3-6 mo on IST; RACE PMID 34986284); ciclosporin trough levels + renal/hepatic function; eltrombopag LFTs + clonal-evolution surveillance (cytogenetics/marrow if cytopenias worsen or dysplasia emerges); serial PNH-clone flow; transfusion burden + ferritin; ATG serum-sickness watch d7-14 (BSH 2024 PMID 38247114; DeZern PMID 34156438)

Disposition

Current setting: outpatient — Confirm acquired AA + exclude hypoplastic MDS / PNH / IBMFS; stratify Camitta severity; deliver IST monitoring + supportive care + clonal-evolution surveillance for non-severe / stable AA (BSH 2024 PMID 38247114)

Disposition criteria:
- Continue outpatient IST + supportive care if non-severe / stable responder (BSH 2024 PMID 38247114)
- Refer for HSCT if young SAA/vSAA with HLA-matched sibling or IST-refractory (ASTCT 2024 PMID 39307421)
- Escalate to inpatient for IST induction / sepsis / severe bleeding (BSH 2024 PMID 38247114)

Escalation triggers (move to higher acuity):
- Fever / suspected neutropenic sepsis → ED + empiric antipseudomonal within 60 min (BSH 2024 PMID 38247114)
- Platelets <10×10⁹/L or any significant bleeding → urgent platelet transfusion (BSH 2024 PMID 38247114)
- Progression to SAA/vSAA (Camitta) → inpatient IST induction or HSCT (Camitta PMID 2893118)
- New circulating blasts / evolving dysplasia → clonal-evolution route (heme.acute-leukemia.core.v1)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Very-severe AA: hypocellular marrow + ANC <0.2×10⁹/L (plus SAA criteria) (Camitta PMID 2893118)
- [LIFE_THREATENING] Temperature ≥38.0°C with ANC <0.5×10⁹/L in SAA/vSAA (BSH 2024 PMID 38247114)
- [LIFE_THREATENING] Rapidly progressive marrow failure with antecedent/concurrent seronegative hepatitis ± hepatic failure (hep-AA series PMID 32925550)

Citations

- BSH 2024 adult aplastic anaemia guideline (supersedes BSH 2016 Killick) + BSH paediatric amendment + ASTCT 2024 allo-HCT guideline + RACE NEJM 2022 + Camitta criteria [PMID:38247114](https://pubmed.ncbi.nlm.nih.gov/38247114/)
- Cited evidence (PMID 26568159) [PMID:26568159](https://pubmed.ncbi.nlm.nih.gov/26568159/)
- Cited evidence (PMID 29285764) [PMID:29285764](https://pubmed.ncbi.nlm.nih.gov/29285764/)
- Cited evidence (PMID 39307421) [PMID:39307421](https://pubmed.ncbi.nlm.nih.gov/39307421/)
- Cited evidence (PMID 34986284) [PMID:34986284](https://pubmed.ncbi.nlm.nih.gov/34986284/)

Last reconciled with current guidelines: 2026-05-16.
References
  • BSH 2024 adult aplastic anaemia guideline (supersedes BSH 2016 Killick) + BSH paediatric amendment + ASTCT 2024 allo-HCT guideline + RACE NEJM 2022 + Camitta criteria — PMID:38247114
  • Cited evidence (PMID 26568159) — PMID:26568159
  • Cited evidence (PMID 29285764) — PMID:29285764
  • Cited evidence (PMID 39307421) — PMID:39307421
  • Cited evidence (PMID 34986284) — PMID:34986284